Drug giant Lilly backs Cambridge's Dicerna in $200M deal
October 29, 2018 at 06:00 AM EDT
The Cambridge biotech is eligible to earn up to $3.7 billion through the deal, with $200 million upfront.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|